Lancet
PHOTON: Intravitreal Aflibercept 8 mg in Diabetic Macular Edema
Brown DM, Boyer DS, Do VD, et al
In the randomised, double-masked, non-inferiority, phase 2/3 PHOTON trial, the authors investigated whether a high-dose formulation of intravitreal aflibercept (8 mg) could improve treatment outcomes in patients with diabetic macular edema by requiring fewer injections than aflibercept 2 mg. Aflibercept 8 mg was safe and effective, with extended dosing intervals that may decrease treatment burden in this patient population.
Previous Article
- • Deep Learning-Assisted Analysis of Biomarker Changes in Therapy-Resistant Neovascular Age-Related Macular Degeneration
- • Real-World Safety and Efficacy of 8 mg Aflibercept in nAMD
- • Case Report: Aflibercept for DME in Vitrectomized Eyes
- • Guideline Recommendations for Optimal Anti-VEGF Therapy in AMD
- • AI-Assisted Fluid Volume Analysis of Treatment-Naive nAMD in the Real World
- • Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative AMD
- • Outcomes of High-Dose Aflibercept in Exudative nAMD
- • PULSAR: Intravitreal Aflibercept 8 mg in nAMD
- • PHOTON: Intravitreal Aflibercept 8 mg in Diabetic Macular Edema
- • CANDELA: Aflibercept 8 mg in Patients With nAMD
